The future of prenatal care just took a leap onto Wall Street. Pulsenmore Ltd., a pioneer in the digital health space, officially commenced trading on the Nasdaq Capital Market this week, a pivotal move that signals a major push for its groundbreaking home-use ultrasound technology in the United States. The company’s shares now trade under the ticker symbol PLSM, maintaining a dual listing alongside the Tel Aviv Stock Exchange (TASE).
The Nasdaq debut, which kicked off on January 21, 2026, is far more than a financial transaction; it’s a strategic effort to accelerate the company’s expansion across the American healthcare system. Pulsenmore is at the forefront of a major shift in maternal health, having developed what it calls the first and only FDA-authorized home-use prenatal ultrasound system.
Ultrasound Imaging from the Living Room
Pulsenmore’s core technology is designed to revolutionize how expectant mothers receive monitoring and care. The system consists of a proprietary, portable ultrasound device that pairs with a patient’s smartphone. The mother can perform a self-administered scan from the comfort of her home, guided either by a mobile app or a clinician in real-time via a secure telehealth platform. The resulting images and video are then securely transmitted to a healthcare provider for remote clinical review.
This remote monitoring solution directly addresses some of the most pressing challenges in modern obstetrics. For women living in rural or underserved areas, or those managing high-risk pregnancies that require frequent in-person checkups, the ability to perform physician-supervised scans at home can significantly improve access to consistent care and reduce travel burden.
Dr. Elazar Sonnenschein, Pulsenmore’s CEO and founder, described the Nasdaq listing as a “transformative step” for the company. The listing is expected to boost the company’s visibility and liquidity, providing a robust platform to engage with a broader, global investor base, which is crucial for their mission-driven growth strategy.
The Market Reaction and Future Trajectory
The initial market reception was notably volatile, a common characteristic for new listings in the technology sector. On its first day of trading, the stock saw a significant price range, opening the door for high activity. Shares traded between a low of $6.35 and a high of $10.28, eventually closing the day at $7.36. The company’s current market capitalization sits around $40 to $48 million.
While the firm has demonstrated strong three-year revenue growth, analysts have also noted the company’s negative operating and net margins in its latest reports, indicating that its current financial strategy is heavily focused on operational expansion and market capture. However, the clear regulatory pathway established by the FDA authorization in late 2025, a milestone which previously caused a surge in its Israeli-listed shares, positions Pulsenmore well to capitalize on the vast American prenatal care market.
As the company continues to establish partnerships with leading U.S. medical centers, its successful Nasdaq debut serves as a strong endorsement of the rising global confidence in telehealth and remote patient monitoring as essential tools for the future of medicine.